Skip to main content

Table 1 Baseline characteristics of 150 women living with HIV, included in the study

From: Bacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark

Demographic data

Study Participants

Duration of HIV infection (years), median (IQR)

11.3 (6.6–16.1)

Age at inclusion (years), median (IQR)

41.1 (36.5–45.5)

Ethnicity, n (%)

 Black

71 (47.3)

 White

53 (35.3)

 Asian

24 (16.0)

 Other

2 (1.3)

Place of HIV transmission, n (%)

 Denmark

45 (32.4)

 Europe + US

13 (9.4)

 Africa

61 (43.9)

 Asia

20 (14.4)

 (missing)

(11)

Mode of transmission, n (%)

 Heterosexual

137 (93.8)

 IDUa

4 (2.7)

 Other

5 (3.4)

 (missing)

(4)

CD4 count (cells/μl), n (%)

  < 200

4 (2.9)

 200–350

18 (13.0)

  > 350

118 (84.1)

 (missing)

(11)

ART, n (%)

 Yes

144 (96.0)

 No

6 (4.0)

ART groups, n (%)

 2 NRTI’s + 1 NNRTI

59 (50.0)

 2 NRTI’s + PI’s

65 (45.1)

 Other regimen

20 (13.9)

AIDS prior to inclusion n (%)

 Yes

20 (13.3)

 No

130 (86.7)

Number of lifetime sexual partners

  < 5

38 (25.3)

 5–14

62 (41.3)

 15–25

24 (16.0)

  > 25

25 (16.7)

 Does not want to respond

1 (0.7)

Current use of contraception n (%)

 Condom Yes

67 (44.7)

 Condom No

83 (55.3)

Symptomsb from the lower abdomen

 Yes

35 (23.3)

 No

115 (76.7)

  1. ART groups: NRTI Nucleoside Reverse Transcriptase Inhibitors, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors, PI Protease Inhibitors
  2. a IDU Intravenous Drug Use
  3. bSymptoms included: increased vaginal discharge, disturbing vaginal smell, burning sensation upon urination, bleeding disturbances, bleeding during intercourse, pain during intercourse, general pain and “other”